Pieter T de Boer1, Pascal Crépey2, Richard J Pitman3, Bérengère Macabeo4, Ayman Chit5, Maarten J Postma6. 1. Unit of PharmacoTherapy, -Epidemiology & -Economics (PTE2), Department of Pharmacy, University of Groningen, Groningen, The Netherlands. Electronic address: p.t.de.boer@rug.nl. 2. EHESP Rennes, Sorbonne Paris-Cité, Paris, France; Aix-Marseille Univ, UMR EPV 190, Marseille, France. 3. ICON Health Economics, Oxford, UK. 4. Sanofi Pasteur, Lyon, France. 5. Sanofi Pasteur, Swiftwater, PA, USA; Lesli Dan Faculty of Pharmacy, Toronto, Ontario, Canada. 6. Unit of PharmacoTherapy, -Epidemiology & -Economics (PTE2), Department of Pharmacy, University of Groningen, Groningen, The Netherlands; Institute of Science in Healthy Aging & healthcaRE (SHARE), University Medical Center Groningen (UMCG), Groningen, The Netherlands; Department of Epidemiology, University Medical Center Groningen (UMCG), University of Groningen, Groningen, The Netherlands.
Abstract
BACKGROUND: Designed to overcome influenza B mismatch, new quadrivalent influenza vaccines (QIVs) contain one additional B strain compared with trivalent influenza vaccines (TIVs). OBJECTIVE: To examine the expected public health impact, budget impact, and incremental cost-effectiveness of QIV versus TIV in the United States. METHODS: A dynamic transmission model was used to predict the annual incidence of influenza over the 20-year-period of 2014 to 2034 under either a TIV program or a QIV program. A decision tree model was interfaced with the transmission model to estimate the public health impact and the cost-effectiveness of replacing TIV with QIV from a societal perspective. Our models were informed by published data from the United States on influenza complication probabilities and relevant costs. The incremental vaccine price of QIV as compared with that of TIV was set at US $5.40 per dose. RESULTS: Over the next 20 years, replacing TIV with QIV may reduce the number of influenza B cases by 27.2% (16.0 million cases), resulting in the prevention of 137,600 hospitalizations and 16,100 deaths and a gain of 212,000 quality-adjusted life-years (QALYs). The net societal budget impact would be US $5.8 billion and the incremental cost-effectiveness ratio US $27,411/QALY gained. In the probabilistic sensitivity analysis, 100% and 96.5% of the simulations fell below US $100,000/QALY and US $50,000/QALY, respectively. CONCLUSIONS: Introducing QIV into the US immunization program may prevent a substantial number of hospitalizations and deaths. QIV is also expected to be a cost-effective alternative option to TIV.
BACKGROUND: Designed to overcome influenza B mismatch, new quadrivalent influenza vaccines (QIVs) contain one additional B strain compared with trivalent influenza vaccines (TIVs). OBJECTIVE: To examine the expected public health impact, budget impact, and incremental cost-effectiveness of QIV versus TIV in the United States. METHODS: A dynamic transmission model was used to predict the annual incidence of influenza over the 20-year-period of 2014 to 2034 under either a TIV program or a QIV program. A decision tree model was interfaced with the transmission model to estimate the public health impact and the cost-effectiveness of replacing TIV with QIV from a societal perspective. Our models were informed by published data from the United States on influenza complication probabilities and relevant costs. The incremental vaccine price of QIV as compared with that of TIV was set at US $5.40 per dose. RESULTS: Over the next 20 years, replacing TIV with QIV may reduce the number of influenza B cases by 27.2% (16.0 million cases), resulting in the prevention of 137,600 hospitalizations and 16,100 deaths and a gain of 212,000 quality-adjusted life-years (QALYs). The net societal budget impact would be US $5.8 billion and the incremental cost-effectiveness ratio US $27,411/QALY gained. In the probabilistic sensitivity analysis, 100% and 96.5% of the simulations fell below US $100,000/QALY and US $50,000/QALY, respectively. CONCLUSIONS: Introducing QIV into the US immunization program may prevent a substantial number of hospitalizations and deaths. QIV is also expected to be a cost-effective alternative option to TIV.
Authors: Pascal Crépey; Esther Redondo; Javier Díez-Domingo; Raúl Ortiz de Lejarazu; Federico Martinón-Torres; Ángel Gil de Miguel; Juan Luis López-Belmonte; Fabián P Alvarez; Hélène Bricout; Míriam Solozabal Journal: PLoS One Date: 2020-05-21 Impact factor: 3.240
Authors: Gideon O Emukule; Fredrick Otiato; Bryan O Nyawanda; Nancy A Otieno; Caroline A Ochieng; Linus K Ndegwa; Peter Muturi; Godfrey Bigogo; Jennifer R Verani; Philip M Muthoka; Elizabeth Hunsperger; Sandra S Chaves Journal: Open Forum Infect Dis Date: 2019-09-30 Impact factor: 3.835